Billions in profits are at stake for some vaccine makers as the US moves to deliver COVID-19 booster shots to boost Americans’ protection against the virus.
How much the manufacturers will benefit depends on how big the rollout proves to be.
The Biden administration last month announced plans to give boosters to nearly everyone. But US regulators have rejected the across-the-board approach, saying instead that third shots of Pfizer’s vaccine should go to people who are 65 and older and some others at higher rates of COVID-19. is risk.
“This opportunity perfectly reflects the billions of people around the world who will need vaccinations and encouragement,” said Jefferies analyst Michael Yee.
Most of the vaccines so far in the US have come from Pfizer, which developed its shot with Germany’s BioNTech and Moderna. They have vaccinated 99 million and 68 million people respectively. Johnson & Johnson is at number three with about 14 million people.
No one yet knows how many people will get the extra shots. But Morningstar analyst Karen Andersen expects Booster alone to be about $26 billion in global sales next year for Pfizer and BioNTech, and about $14 billion for Moderna, if they are supported for nearly all Americans.
Anderson expects Moderna, which has no other products on the market, to generate about $13 billion in profit from all COVID-19 vaccine sales next year if the boosters are widely authorized.
It’s hard to forecast potential vaccine profits for Pfizer, but company executives have said they expect their pre-tax adjusted profit margin from the vaccine to be in the “high 20” as a percentage of revenue. Based on Andersen’s sales prediction, it’ll be a profit of about $7 billion from just boosters next year.
J&J and Europe’s AstraZeneca have said they do not intend to profit from their COVID-19 vaccines during the pandemic.
For Pfizer and Moderna, boosters may be more profitable than basic doses because they won’t come with the research and development costs that companies incur in getting vaccines to market in the first place.
Steve Brozak, CEO of WBB Securities, said the booster shots would represent an “almost net benefit” compared to the starting dose.
Drugmakers aren’t the only businesses that can see a windfall profit from giving out boosters. According to Jeff Jonas, portfolio manager at Gabelli Funds, drugstore chains CVS Health and Walgreens could each bring in more than $800 million in revenue.
Jonas notes that drugstores may not face competition from mass vaccination clinics this time around, and chains are diligent in collecting customer contact information. This makes it easy to invite people back for boosters.
Drugmakers are also developing COVID-19 shots that target certain types of the virus, and say people may need the annual shots they receive for the flu. All this could make vaccines a major recurring source of revenue.
The COVID-19 vaccines have already done much better than their predecessors.
Pfizer said in July that it expected revenue from its COVID-19 vaccine to reach $33.5 billion this year, an estimate that could change depending on the impact of the booster or the potential expansion of shots for primary school children.
That would be five times more than the $5.8 billion racked last year by the world’s most lucrative vaccine – Pfizer’s Prevnar13, which protects against pneumococcal disease.
It would also reduce the $19.8 billion brought in last year by AbbVie’s rheumatoid arthritis treatment Humira, widely considered the world’s best-selling drug.
This bodes well for future vaccine development, said Eric Gordon, a business professor at the University of Michigan.
Gordon said that vaccines are not usually beneficial as a treatment. But the success of COVID-19 shots could attract more drugmakers and venture capitalists to the sector.
“The vaccine business is more lucrative, which is good for those of us who need vaccines,” Gordon said.
Follow Tom Murphy on Twitter: https://twitter.com/thpmurphy
The Associated Press Department of Health and Science receives support from the Howard Hughes Medical Institute’s Department of Science Education. AP is solely responsible for all content.